DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 56.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,541 shares of the biotechnology company's stock after selling 7,072 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main's holdings in United Therapeutics were worth $1,955,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. Newbridge Financial Services Group Inc. purchased a new stake in United Therapeutics in the fourth quarter worth $25,000. Dunhill Financial LLC grew its holdings in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. Millstone Evans Group LLC purchased a new position in United Therapeutics in the 4th quarter worth about $67,000. MassMutual Private Wealth & Trust FSB boosted its position in United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after buying an additional 58 shares during the period. Finally, Natixis purchased a new stake in United Therapeutics in the 4th quarter valued at about $85,000. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $283.78, for a total value of $3,121,580.00. Following the completion of the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $10,437,712.18. This trade represents a 23.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now owns 8,480 shares of the company's stock, valued at approximately $2,703,424. The trade was a 22.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 65,500 shares of company stock worth $20,765,280 in the last 90 days. 11.90% of the stock is owned by insiders.

Analysts Set New Price Targets

UTHR has been the topic of a number of research reports. JPMorgan Chase & Co. cut their target price on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Bank of America raised shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 price objective on the stock in a report on Monday, April 21st. Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. HC Wainwright reissued a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Finally, Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock traded down $2.73 on Tuesday, reaching $308.07. 757,279 shares of the company were exchanged, compared to its average volume of 441,798. The stock's 50 day moving average price is $300.54 and its 200-day moving average price is $341.52. United Therapeutics Co. has a 1-year low of $264.33 and a 1-year high of $417.82. The company has a market cap of $13.90 billion, a P/E ratio of 13.53, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. During the same period last year, the firm earned $6.17 earnings per share. United Therapeutics's quarterly revenue was up 17.2% on a year-over-year basis. On average, research analysts predict that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.